Susquehanna International Group, LLP Viridian Therapeutics, Inc.\De Put Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2025 Aug 14, 2025	BUY	$11.02 - $16.09 $2.44 Million - $3.57 Million	221,600 Added 2194.06%	231,700 $3.24 Million
Q1 2025 May 14, 2025	SELL	$13.48 - $20.91 $2.71 Million - $4.2 Million	-201,000 Reduced 95.22%	10,100 $136,000
Q4 2024 Feb 14, 2025	BUY	$17.85 - $25.71 $1.99 Million - $2.87 Million	111,600 Added 112.16%	211,100 $4.05 Million
Q3 2024 Nov 14, 2024	BUY	$12.16 - $23.33 $925,376 - $1.78 Million	76,100 Added 325.21%	99,500 $2.26 Million
Q2 2024 Aug 15, 2024	BUY	$11.6 - $17.26 $25,520 - $37,972	2,200 Added 10.38%	23,400 $304,000
Q1 2024 May 07, 2024	BUY	$17.09 - $23.82 $129,884 - $181,032	7,600 Added 55.88%	21,200 $371,000
Q4 2023 Feb 14, 2024	BUY	$11.12 - $22.5 $151,232 - $306,000	13,600 New	13,600 $296,000
Q2 2023 Aug 11, 2023	BUY	$22.57 - $29.67 $5.17 Million - $6.79 Million	228,900 Added 1467.31%	244,500 $5.82 Million
Q1 2023 May 16, 2023	BUY	$25.04 - $37.6 $390,624 - $586,560	15,600 New	15,600 $396,000
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $292,110 - $696,150	27,300 New	27,300 $560,000

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $890M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.